4-(3,4-dichlorophenyl)piperidine-4-carbonitrile hydrochloride | 1071993-16-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(3,4-dichlorophenyl)piperidine-4-carbonitrile hydrochloride
• 英文别名: 4-(3,4-dichlorophenyl)piperidine-4-carbonitrile;hydrochloride
• CAS: 1071993-16-2
• 化学式: C₁₂H₁₂Cl₂N₂*ClH
• 分子量: 291.608
• InChiKey: NTTFLEROIBUSBL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.56
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  35.8
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(3,4-dichlorophenyl)piperidine-4-carbonitrile hydrochloride 在 aluminum (III) chloride 、 lithium aluminium tetrahydride 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 6-(4-(aminomethyl)-4-(3,4-dichlorophenyl)piperidin-1-yl)pyrimidin-4-amine
  参考文献：
  名称：

  Integrating docking scores, interaction profiles and molecular descriptors to improve the accuracy of molecular docking: Toward the discovery of novel Akt1 inhibitors

  摘要：

  A set of forty-seven Akt1 inhibitors was used for the development of molecular docking based QSAR model by using nonlinear regression. The integration of docking scores, key interaction profiles and molecular descriptors remarkably improved the accuracy of the QSAR models, providing reasonable statistical parameters (R-train(2) = 0.948, R-test(2) = 0.907 and Q(cv)(2) = 0.794). The established MD-SVR model based structural modification of new 4-amino-pyrimidine derivatives was further performed, and six compounds 56a,b and 60a-d with good prediction activities were synthesized and biologically evaluated. All of these compounds exhibited promising Akt1 inhibitory and antiproliferative activities, suggesting the reliability and good application value of the established MD-SVR model in the development of Akt1 inhibitors. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.01.019
• 作为产物：
  描述：

  1-benzyl-4-(3,4-dichlorophenyl)piperidine-4-carbonitrile 在 氯甲酸氯乙酯 作用下， 以 甲醇 、 1,2-二氯乙烷 为溶剂， 反应 5.0h， 以90%的产率得到4-(3,4-dichlorophenyl)piperidine-4-carbonitrile hydrochloride
  参考文献：
  名称：

  Integrating docking scores, interaction profiles and molecular descriptors to improve the accuracy of molecular docking: Toward the discovery of novel Akt1 inhibitors

  摘要：

  A set of forty-seven Akt1 inhibitors was used for the development of molecular docking based QSAR model by using nonlinear regression. The integration of docking scores, key interaction profiles and molecular descriptors remarkably improved the accuracy of the QSAR models, providing reasonable statistical parameters (R-train(2) = 0.948, R-test(2) = 0.907 and Q(cv)(2) = 0.794). The established MD-SVR model based structural modification of new 4-amino-pyrimidine derivatives was further performed, and six compounds 56a,b and 60a-d with good prediction activities were synthesized and biologically evaluated. All of these compounds exhibited promising Akt1 inhibitory and antiproliferative activities, suggesting the reliability and good application value of the established MD-SVR model in the development of Akt1 inhibitors. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.01.019

文献信息

• PYRIDAZINE COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP3118200A1

  公开（公告）日：2017-01-18

  The present provides a pyridazine compound having an inhibiting effect on Stearoyl-CoA desaturase (SCD) (in particular, SCD1). The present provides a compound represented by formula (where each symbol is as defined as in the Specification) or a salt thereof

  本发明提供了一种对硬脂酰辅酶A去饱和酶（SCD）（特别是SCD1）具有抑制作用的吡啶啉化合物。本发明提供了一种由以下公式表示的化合物（其中每个符号如规范中定义）或其盐。
• Discovery of Bioavailable 4,4-Disubstituted Piperidines as Potent Ligands of the Chemokine Receptor 5 and Inhibitors of the Human Immunodeficiency Virus-1
  作者：Wieslaw M. Kazmierski、Christopher Aquino、Brian A. Chauder、Felix Deanda、Robert Ferris、Deborah K. Jones-Hertzog、Terrence Kenakin、Cecilia S. Koble、Christian Watson、Pat Wheelan、Hanbiao Yang、Michael Youngman

  DOI：10.1021/jm800598a

  日期：2008.10.23

  We describe robust chemical approaches toward putative CCR5 scaffolds designed in our laboratories. Evaluation of analogues in the (125)I-[MIP-1 beta] binding and Ba-L-HOS antiviral assays resulted in the discovery of 64 and 68 in the 4,4-disubstitited piperidine class H, both potent CCR5 ligands (pIC(50) = 8.30 and 9.00, respectively) and HIV-1 inhibitors (pIC(50) = 7.80 and 7.84, respectively, in Ba-L-HOS assay). In addition, 64 and 68 were bioavailable in rodents, establishing them as lead molecules for further optimization toward CCR5 clinical candidates.